Alprostadil
Alprostadil (CAS 745-65-3), also known as prostaglandin E1, is an endogenous prostaglandin analog that exerts potent vasodilatory activity by binding and activating prostaglandin E-type (EP) receptors, primarily EP2 and EP4. Upon receptor activation, intracellular cyclic adenosine monophosphate (cAMP) levels rise, mediating smooth muscle relaxation and vasodilation. Clinically, Alprostadil is investigated and utilized in research contexts addressing vascular biology, erectile dysfunction mechanisms, and cardiovascular function, offering insights into prostaglandin signaling pathways.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 354.48 |
| Cas No. | 745-65-3 |
| Formula | C20H34O5 |
| Solubility | insoluble in H2O; ≥13.4 mg/mL in DMSO; ≥47.1 mg/mL in EtOH |
| Chemical Name | 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid |
| SDF | Download SDF |
| Canonical SMILES | CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Human umbilical vein endothelial cells (HUVECs) |
|
Reaction Conditions |
0 ~ 10 μM alprostadil |
|
Applications |
Alprostadil (1 nM ~ 10 μM; 48 h) concentration-dependently reduced HUVEC proliferation (up to 100% inhibition) in the presence of 20 ng/mL vascular endothelial growth factor (VEGF), with an IC50 of 400 nM. Alprostadil (0.01 ~ 10 μM; 6 h) also inhibited VEGF-induced HUVEC migration in a concentration dependent manner, with an IC50 of 500 nM. |
| Animal experiment:[1] | |
|
Animal models |
Female C57/bl6 mice, 6 ~ 8 weeks of age |
|
Dosage form |
20 ng Administered subcutaneously for 4 days |
|
Applications |
Alprostadil treatment (20 ng/animal/day; 4 days) significantly inhibited the fibroblast growth factor (FGF)-induced angiogenesis in mice. Alprostadil could be useful for diseases that require anti-angiogenic therapy, such as diabetic retinopathy and solid tumors. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Cattaneo MG, Pola S, Dehò V, et al. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. British Journal of Pharmacology, 2003, 138(2): 377-385. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
